3 Future Stars in Big Pharma's Best Pipeline

Health care leader Johnson & Johnson's drug business is only one part of this company's diversified medical portfolio, but it has recently emerged as J&J's biggest division by sales. Drug sales jumped almost 10% for Johnson & Johnson in the third quarter alone, surpassing medical devices in total revenues. That was thanks to the gains made by old, reliable drugs like immunology blockbuster Remicade, as well as up-and-coming drugs that are lighting up investors' hopes for the future.

But Johnson & Johnson's not a company to sit on its laurels. Its pipeline is packed with punch to continue its pharmaceutical success long into the future. So, which drugs under development do investors need to keep an eye on?

In the video below, Fool contributor Dan Carroll highlights three key drugs in Johnson & Johnson's drug pipeline that could emerge as major players in this health care giant's future -- and what they could mean for this stock's long-term future.

Is Johnson & Johnson the best dividend stock for your money?
Johnson & Johnson's steady, reliable performance over the years has made this stock one tried-and-true blue-chip pick that dividend investors can count on. However, the best income investors understand the power of a portfolio's diversity. Which are the best dividend stocks around the market that should catch your eye? Our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

The article 3 Future Stars in Big Pharma's Best Pipeline originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Celgene and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story